Successful Management of Esophageal Cancer With Perforation Using Bypass Surgery Followed by Definitive Chemoradiotherapy.


Journal

In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809

Informations de publication

Date de publication:
Historique:
received: 18 03 2020
revised: 31 03 2020
accepted: 01 04 2020
entrez: 2 7 2020
pubmed: 2 7 2020
medline: 22 6 2021
Statut: ppublish

Résumé

Esophageal perforation in advanced esophageal cancer requires immediate treatment. However, no clear treatment protocol has been established for this condition. We report a case of advanced esophageal cancer with esophageal perforation treated with esophageal bypass surgery and definitive chemoradiotherapy (CRT). A 45-year-old woman was diagnosed with locally advanced esophageal cancer with esophageal perforation. Although the patient's general condition was relatively stable, no improvement was expected through conservative treatment. Esophageal gastric bypass surgery was performed; her symptoms improved postoperatively and oral ingestion became possible. Definitive CRT with 66 Gy radiotherapy and chemotherapy with cisplatin and 5-fluorouracil was administered. A complete clinical response was achieved. The patient is alive and well without recurrence 20 months after treatment. Definitive CRT after esophageal bypass surgery is a potential treatment option for locally advanced esophageal cancer with esophageal perforation to improve treatment response and quality of life.

Sections du résumé

BACKGROUND BACKGROUND
Esophageal perforation in advanced esophageal cancer requires immediate treatment. However, no clear treatment protocol has been established for this condition. We report a case of advanced esophageal cancer with esophageal perforation treated with esophageal bypass surgery and definitive chemoradiotherapy (CRT).
CASE REPORT METHODS
A 45-year-old woman was diagnosed with locally advanced esophageal cancer with esophageal perforation. Although the patient's general condition was relatively stable, no improvement was expected through conservative treatment. Esophageal gastric bypass surgery was performed; her symptoms improved postoperatively and oral ingestion became possible. Definitive CRT with 66 Gy radiotherapy and chemotherapy with cisplatin and 5-fluorouracil was administered. A complete clinical response was achieved. The patient is alive and well without recurrence 20 months after treatment.
CONCLUSION CONCLUSIONS
Definitive CRT after esophageal bypass surgery is a potential treatment option for locally advanced esophageal cancer with esophageal perforation to improve treatment response and quality of life.

Identifiants

pubmed: 32606200
pii: 34/4/2169
doi: 10.21873/invivo.12025
pmc: PMC7439868
doi:

Substances chimiques

Cisplatin Q20Q21Q62J
Fluorouracil U3P01618RT

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2169-2172

Informations de copyright

Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Références

Am J Surg. 2007 Jun;193(6):792-3
pubmed: 17512299
J Clin Oncol. 1999 Sep;17(9):2915-21
pubmed: 10561371
Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):134-9
pubmed: 12007951
Ann Thorac Surg. 2000 Dec;70(6):1803-7
pubmed: 11156075
World J Surg. 2005 Jan;29(1):25-30; discussion 30-1
pubmed: 15599735
Abdom Imaging. 2001 Nov-Dec;26(6):565-9
pubmed: 11911165
Ann Thorac Surg. 2004 Apr;77(4):1475-83
pubmed: 15063302
Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1327-32
pubmed: 12873677
Acta Radiol. 2006 Feb;47(1):3-9
pubmed: 16498926
Ann Surg. 1979 Jun;189(6):673-6
pubmed: 453939
Surg Today. 2011 Apr;41(4):560-2
pubmed: 21431494
Br J Cancer. 2003 Jan 13;88(1):18-24
pubmed: 12556953
Int J Clin Oncol. 2003 Dec;8(6):395-8
pubmed: 14663644
Jpn J Surg. 1989 Mar;19(2):182-8
pubmed: 2724717
Ann Thorac Surg. 2014 Jan;97(1):290-5
pubmed: 24200399
Aliment Pharmacol Ther. 2007 Apr 15;25(8):955-63
pubmed: 17403000
Surgery. 1970 Feb;67(2):293-301
pubmed: 5411292
Ann Thorac Cardiovasc Surg. 2011;17(3):221-8
pubmed: 21697781
Cancer Sci. 2007 Jul;98(7):937-42
pubmed: 17441965

Auteurs

Manato Ohsawa (M)

Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan.

Yoichi Hamai (Y)

Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan yyhamai@hotmail.com.

Yuta Ibuki (Y)

Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan.

Manabu Emi (M)

Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan.

Morihito Okada (M)

Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH